Abstract PO-020: Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2- mBC patients during the pandemic
Pablo Tolosa(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Mercedes Herrera(University of Córdoba), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Ana Sánchez(Research Institute Hospital 12 de Octubre), Helena Bote de Cabo(Research Institute Hospital 12 de Octubre), Laura Lema(Hospital Universitario 12 De Octubre), Ramón Yarza(Research Institute Hospital 12 de Octubre)
Cited by 2
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268